Total Payments
$5,589
2024 Payments
$920.91
Companies
37
Transactions
264
Medicare Patients
2,034
Medicare Billing
$436,471
Payment Breakdown by Category
Food & Beverage$5,462 (97.7%)
Education$66.82 (1.2%)
Gifts$59.40 (1.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,462 | 259 | 97.7% |
| Education | $66.82 | 4 | 1.2% |
| Gift | $59.40 | 1 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $819.89 | 61 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $377.41 | 17 | $0 (2021) |
| Amgen Inc. | $371.31 | 17 | $0 (2024) |
| Dexcom, Inc. | $352.19 | 5 | $0 (2024) |
| Lilly USA, LLC | $328.20 | 23 | $0 (2024) |
| W. L. Gore & Associates, Inc. | $324.97 | 2 | $0 (2019) |
| GENZYME CORPORATION | $318.97 | 13 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $235.84 | 23 | $0 (2024) |
| Medtronic MiniMed, Inc. | $204.22 | 14 | $0 (2019) |
| Horizon Therapeutics plc | $183.98 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $920.91 | 41 | Novo Nordisk Inc ($183.17) |
| 2023 | $178.51 | 4 | Horizon Therapeutics plc ($165.04) |
| 2022 | $253.39 | 16 | Insulet Corporation ($75.02) |
| 2021 | $219.28 | 14 | Novo Nordisk Inc ($50.62) |
| 2020 | $51.15 | 3 | Dexcom, Inc. ($21.67) |
| 2019 | $1,666 | 80 | GENZYME CORPORATION ($219.82) |
| 2018 | $1,758 | 92 | AstraZeneca Pharmaceuticals LP ($242.43) |
| 2017 | $540.65 | 14 | W. L. Gore & Associates, Inc. ($196.91) |
All Payment Transactions
264 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Verity Pharmaceuticals Inc. | Tlando (Drug) | Food and Beverage | Cash or cash equivalent | $38.27 | General |
| Category: Testosterone Replacement Therapy (TRT) | ||||||
| 12/19/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $7.73 | General |
| 12/17/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: Endocrinology | ||||||
| 12/11/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $24.79 | General |
| 12/10/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $40.46 | General |
| Category: Endocrinology | ||||||
| 12/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $22.80 | General |
| Category: Obesity | ||||||
| 11/20/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $26.83 | General |
| 11/15/2024 | Boston Scientific Corporation | EMBLEM MRI S-ICD (Device) | Food and Beverage | In-kind items and services | $20.43 | General |
| Category: EMBLEM_CRM | ||||||
| 11/14/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $16.77 | General |
| 11/12/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: Endocrinology | ||||||
| 11/07/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $26.73 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $10.31 | General |
| 11/06/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: Diabetes | ||||||
| 11/05/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: LIVER DISEASE | ||||||
| 10/29/2024 | Verity Pharmaceuticals Inc. | Tlando (Drug) | Food and Beverage | Cash or cash equivalent | $37.35 | General |
| Category: Testosterone Replacement Therapy (TRT) | ||||||
| 10/13/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: Endocrinology | ||||||
| 10/10/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $12.15 | General |
| Category: Diabetes | ||||||
| 09/25/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $33.44 | General |
| Category: IMMUNOLOGY | ||||||
| 09/17/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: Endocrinology | ||||||
| 08/21/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $30.06 | General |
| Category: IMMUNOLOGY | ||||||
| 08/20/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $20.45 | General |
| 08/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $22.64 | General |
| Category: Obesity | ||||||
| 07/30/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $30.44 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 07/25/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: Endocrinology | ||||||
| 07/23/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $30.88 | General |
| Category: Bone Health | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 591 | 7,036 | $400,255 | $148,318 |
| 2022 | 6 | 541 | 2,933 | $283,121 | $112,380 |
| 2021 | 10 | 498 | 2,590 | $180,461 | $106,870 |
| 2020 | 6 | 404 | 1,727 | $130,815 | $68,903 |
Total Patients
2,034
Total Services
14,286
Medicare Billing
$436,471
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 364 | 747 | $211,761 | $72,029 | 34.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 61 | 6,060 | $153,000 | $63,510 | 41.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 62 | 62 | $22,730 | $8,728 | 38.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 44 | 94 | $7,058 | $2,553 | 36.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 12 | 13 | $3,705 | $808.25 | 21.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 48 | 60 | $2,001 | $689.04 | 34.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 312 | 649 | $184,207 | $64,771 | 35.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 31 | 1,997 | $56,739 | $31,042 | 54.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 66 | 66 | $24,090 | $8,251 | 34.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 50 | 65 | $9,225 | $5,097 | 55.3% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 36 | 82 | $5,664 | $2,350 | 41.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 46 | 74 | $3,196 | $869.68 | 27.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 262 | 570 | $99,180 | $58,899 | 59.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 16 | 1,680 | $45,360 | $28,042 | 61.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 57 | 90 | $11,700 | $7,739 | 66.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 42 | 42 | $11,130 | $5,877 | 52.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 17 | 20 | $4,620 | $3,044 | 65.9% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 25 | 64 | $4,352 | $1,778 | 40.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 40 | 74 | $3,256 | $826.24 | 25.4% |
| 0012A | Adm sarscov2 100mcg/0.5ml2nd | Office | 2021 | 14 | 14 | $588.00 | $449.96 | 76.5% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 11 | 11 | $275.00 | $214.17 | 77.9% |
| 91301 | Sarscov2 vac 100mcg/0.5ml im | Office | 2021 | 14 | 25 | $0.25 | $0.25 | 100.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 220 | 409 | $71,166 | $35,393 | 49.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 14 | 1,080 | $29,160 | $17,059 | 58.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 57 | 87 | $10,653 | $7,415 | 69.6% |
About Dr. Jennifer Chang, M.D
Dr. Jennifer Chang, M.D is a Internal Medicine healthcare provider based in Pasadena, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/28/2008. The National Provider Identifier (NPI) number assigned to this provider is 1568631091.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jennifer Chang, M.D has received a total of $5,589 in payments from pharmaceutical and medical device companies, with $920.91 received in 2024. These payments were reported across 264 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($5,462).
As a Medicare-enrolled provider, Chang has provided services to 2,034 Medicare beneficiaries, totaling 14,286 services with total Medicare billing of $436,471. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism
- Location Pasadena, CA
- Active Since 02/28/2008
- Last Updated 01/20/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1568631091
Products in Payments
- VIABAHN VBX Balloon Expandable Endoprosthesis (Device) $324.97
- KEVZARA (Drug) $318.97
- FARXIGA (Drug) $311.24
- AFREZZA (Drug) $178.29
- Endurant (Device) $176.73
- TEPEZZA (Drug) $165.04
- OCA (Drug) $160.35
- EVENITY (Biological) $142.10
- Dexcom CGM (Device) $141.86
- Omnipod (Device) $138.73
- DEXCOM CGM (Device) $129.94
- Saxenda (Drug) $127.85
- BENLYSTA (Biological) $124.68
- Minimed 670G System (Device) $123.10
- Ozempic (Drug) $118.82
- Korlym (Drug) $118.73
- HUMULIN (Drug) $114.55
- Victoza (Drug) $107.78
- Prolia (Biological) $104.84
- PNEUMOVAX 23 (Biological) $104.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Pasadena
Dr. Yuan Yuan, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $523,801
Internal Medicine $523,801
Christopher Dagher, M.d, M.D
Internal Medicine — Payments: $103,615
Internal Medicine $103,615
Peter Haddad, M.d, M.D
Internal Medicine — Payments: $87,600
Internal Medicine $87,600
Dr. Andrew Williams, M.d, M.D
Internal Medicine — Payments: $85,273
Internal Medicine $85,273
Joseph Dellinger, Md, MD
Internal Medicine — Payments: $77,175
Internal Medicine $77,175
Dr. Helen Moon, M.d, M.D
Internal Medicine — Payments: $61,882
Internal Medicine $61,882